Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
414 results about "Colon cancer cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cancer that starts in the colon or rectum is often called colorectal cancer. It starts when cells in the colon or rectum grow out of control and crowd out normal cells. This makes it hard for the body to work the way it should.
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
InactiveUS6923958B2Enhance immune responseEffective immune responseOrganic active ingredientsPeptide/protein ingredientsLipofectamineMammal
A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40 ligand, SEQ ID NO:1 and SEQ ID NO: 2, respectively, or its homotrimer, CD40LT. The DNA vaccine can be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier. In a method embodiment, the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells. A preferred method embodiment includes the additional step of treating the mammal with recombinant antibody fusion protein huKS1 / 4-IL2 to enhance the immune response effectiveness of the vaccine.
Owner:THE SCRIPPS RES INST
Antibodies against cancer
InactiveUS7318924B2Improve permeabilityPeptide/protein ingredientsGenetic material ingredientsAnticarcinogenCripto
Owner:THE MACFARLANE BURNET INST FOR MEDICAL RES & PUBLIC HEALTH LTD
Bifidobacterium bifidum and application thereof
ActiveCN106834187AImprove toleranceIncrease the water content of fecesBacteriaDigestive systemSide effectFeces
The invention discloses bifidobacterium bifidum capable of remarkably relieving constipation and application thereof and belongs to the technical field of microorganisms. The bifidobacterium bifidum CGMCC NO.13632 can well tolerate simulative gastrointestinal fluid, can be well attached to colon cancer cells HT-29, and can remarkably increase the water content of excrement of constipation mice and shorten the first tarry stool time. On the aspect of increasing the small intestine driving rate, the bifidobacterium bifidum CGMCC NO.13632 is superior to cathartic phenolphthalein, a best effect is shown, secretion of gastrointestinal regulatory peptide relevant to constipation in serum is also adjusted while constipation pathological factors are remarkably improved, and the bifidobacterium bifidum does not have toxic and side effects of medicine for treating constipation, and is a first choice for preventing and treating constipation. The bifidobacterium bifidum CGMCC NO.13632 is used for preparing pharmaceutical compositions and fermented food for relieving constipation, and has very wide application prospects.
Owner:JIANGNAN UNIV
Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor
InactiveUS20030134001A1Significant health advantageBig advantageBiocideUnknown materialsGrowth retardantTreatment effect
The present invention features methods and formulations or compositions for the treatment of colon cancer, and particularly for the inhibition, prevention and / or reduction of cancerous cell growth, as well as the destruction of early stage cancerous cells within the colon region of a mammal, wherein the formulations and compositions comprise an identified amount or concentration of a processed Morinda citrifolia product or an active ingredient there from, as obtained from the Indian Mulberry plant.
Owner:TAHITIAN NONI INT INC
Antibodies against cancer
InactiveUS20040176576A1Reduce the number of cellsEnhanced inhibitory effectPeptide/protein ingredientsGenetic material ingredientsAnticarcinogenCripto
An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitising a cancer cell to a cytotoxic compound. In addition, a cancer Vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.
Owner:THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD
Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor
The present invention features methods and formulations or compositions for the treatment of colon cancer, and particularly for the inhibition, prevention and / or reduction of cancerous cell growth, as well as the destruction of early stage cancerous cells within the colon region of a mammal, wherein the formulations and compositions comprise an identified amount or concentration of a processed Morinda citrifolia product or an active ingredient there from, as obtained from the Indian Mulberry plant.
Owner:TAHITIAN NONI INT INC
Targeted adriamycin-loaded magnetic nanoparticles and preparation method and application
InactiveCN106729773AGood target recognition abilityExcellent photothermal killing functionOrganic active ingredientsEnergy modified materialsEGFR AntibodyMagnetite Nanoparticles
The invention provides a targeted adriamycin-loaded magnetic nanoparticles and a preparation method and application, and belongs to the magnetic nanoparticles and preparation thereof. The targeted adriamycin-loaded magnetic nanoparticles are formed by taking the magnetic Fe3O4 nanoparticles formed by using dopamine to wrap as a core, and an EGFR antibody covalently coupled on the surface of the magnetic Fe3O4 nanoparticles through 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride or N-hydroxysuccinimide, and adriamycin non-covalently coupled to the surface of the nanoparticles. The nanoparticles provided by the invention have good target recognition capacity to the colon cancer cell DLD-1, can effectively enter the internal of the DLD-1 cell, has excellent photo-thermal killing ability on the DLD-1 cell, can be used for the photo-thermal treatment and medicine chemotherapy of the colon cancer cell, and has a good magnetic resonance imaging function.
Owner:JILIN UNIV
Ziyang selenium-rich green tea selenium-containing polysaccharide, and preparation method and application thereof
ActiveCN102417544AProtectiveHigh purityOrganic active ingredientsDigestive systemHeterosaccharideLactose
The invention discloses a Ziyang selenium-rich green tea selenium-containing polysaccharide, which comprises the following components in percentage by mass: 1.5-8.5 ppm selenium and the balance of heterosaccharide. The heterosaccharide comprises the following components in percentage by mol: 3.3-5.3% of mannitose, 1-2% of ribose, 3.5-5% of rhamnose, 2-3.5% of glucuronic acid, 2.6-3.8% of galacturonic acid, 30-34.2% of glucose, 3.6-5.6% of xylose, 19.8-23.2% of galactose and 21.5-25.6% of arabinose. The invention also provides a preparation method and application of the Ziyang selenium-rich green tea selenium-containing polysaccharide. The preparation method is simple and convenient, has the advantage of low cost, and is suitable for popularization; and the selenium-containing polysaccharide has the action of enhancing immunity, has obvious inhibiting actions on growth of colon cancer cells, and has obvious protective actions on hepatic injury.
Owner:SHAANXI NORMAL UNIV
Compound with MEK (Mitogen-activated and Extracellular signal-regulated Kinase) inhibiting function as well as preparation method and application of compound
The invention discloses a compound with an MEK (Mitogen-activated and Extracellular signal-regulated Kinase) inhibiting function as well as a preparation method and application of the compound. The structure of the compound disclosed by the invention is as shown in a formula (I). The preparation method of the compound disclosed by the invention comprises the steps of forming a coumarin ring by adopting a Pechmann reaction mainly and carrying out structural modification of different sites. In the binding experiment of the compound disclosed by the invention and MEK, the binding activity is up to 54.57nM; the anti-proliferation effect IC50 (half maximal inhibitory concentration) value on the melanoma cell A375 is up to 1.23 micrometers; the anti-proliferation effect IC50 value on the colon cancer cell HT-29 is up to 2.13 micrometers; and the activity is higher than that of a positive control U0126. The novel structure type coumarins compound with the MEK inhibiting function shows good MEK binding activity, MEK inhibiting activity, ERK (Extracellular signal Regulated Kinase) pathway inhibiting activity, anti-tumor effect and antiviral effect and has broad application value. The formula (I) is as shown in the specification.
Owner:PEKING UNIV
Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimarker quantitative RT-PCR
InactiveUS7910295B2High sensitivityStrong specificityMicrobiological testing/measurementBiological testingAbnormal tissue growthMetastatic melanoma
The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and β-HCG.
Owner:JOHN WAYNE CANCER INST
Lactic acid bacterium used for fermenting cereal and applications thereof
ActiveCN103468600AHas anti-tumor functionWith independent intellectual property rightsBacteriaMicroorganism based processesHordeum vulgareApoptosis
The invention discloses a lactic acid bacterium used for fermenting cereal and applications thereof, and belongs to the field of food biotechnology. Lactic acid bacterium Dy-1, suggested classification name is Lactobacillus plantarum, is delivered to China General Microbiological Culture Collection Center, Institute of Microbiology, China Academy of Science, in No.1 yard, No.3 building, Beichenxi road, Chaoyang district, Beijing, China, at April, 18th, 2012 for preservation, and the preservation number is CGMCC No.6016. Applications of the lactic acid bacterium comprise following steps: wheat germ or barley is fermented by freeze-dried powder of the lactic acid bacterium; a fermentation broth is subjected to centrifugation so as to obtain a supernatant; and the supernatant is subjected to freeze drying so as to obtain a fermentation extract. The fermentation extract possesses significant apoptosis promoting and propagation inhibiting effects on HT-29 colon cancer cells and SGC-7901 stomach cancer cells, and significant inhibiting effect on tumor growth of HT-29 colon cancer induced tumor-bearing nude mice models, and is capable of improving immunity of the HT-29 colon cancer induced tumor-bearing nude mice models.
Owner:JIANGSU UNIV
Method for screening colon cancer cells and gene set used for examination of colon cancer
InactiveUS20090011413A1Improve accuracyHigh-precision detectionSugar derivativesMicrobiological testing/measurementGene listColon cancer cell
Colon cancer cells in a sample are screened by analyzing the amount of expression of at least 2 or more genes or products thereof selected from the group of genes listed in Tables 1 and 30. As compared to conventional method, patients having colon cancer can be detected with higher accuracy. Colon cancer cells in stool are also screened by analyzing expression of genes selected from the group of genes listed in Table 37.
Owner:CANON KK +1
Bifidobacterium bifidum and its use
ActiveCN106834187BIncrease moisture contentImprove the first black stool timeBacteriaDigestive systemBiotechnologySide effect
Owner:JIANGNAN UNIV
Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimarker quantitative RT-PCR
InactiveUS20040265845A1High sensitivityStrong specificityMicrobiological testing/measurementBiological testingAbnormal tissue growthLymphatic Spread
The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and beta-HCG.
Owner:JOHN WAYNE CANCER INST
Application of echinacoside in anti-tumor medicaments
ActiveCN104288170AInhibitory activityBlock scavenging oxidationOrganic active ingredientsAntineoplastic agentsMalachite greenCancer cell
The invention relates to application of echinacoside in anti-tumor medicaments. The application provided by the invention is as follows: firstly adding MTH1, inorganic pyrophosphatase and dGTP into a reaction solution (100mM pH 8.0 Tris-acetic acid, 40mM NaCl, 10mM magnesium acetate, 0.005% Tween 20 and 1mM DTT), incubating an enzyme and a substrate at room temperature for 1h, then adding 25 mu l of malachite green solution to terminate reaction and performing absorbance detection at 630nm by using an iMark microplate reader, wherein results show that echinacoside has a significant effect of inhibiting enzyme activity of MTH1; and secondly detecting the effects of echinacoside against tumor cells at the cellular level by an MTT experiment, wherein the results show that echinacoside can obviously inhibit the growth of SW480 colon cancer cells and U2OS human osteosarcoma cells. According to the application provided by the invention, echinacoside is used for inhibiting specific enzyme MTH1 for maintaining survival in the tumor cells, and oxidized nucleotide is mixed into DNA, thereby resulting in fatal DNA double-strand break in the cancer cells, producing an anti-tumor effect, finding a new medical use of echinacoside and laying a foundation for future development of the new anti-tumor medicaments.
Owner:JILIN UNIV
Anti-tumor medicine
InactiveCN101103973AOrganic active ingredientsAntineoplastic agentsAbnormal tissue growthProstate cancer cell
Disclosed is an anti-tumor drug with nor-icariin as the effective ingredient. Pharmacological test effect proves that the nor-icariin has the activity to inhibit the production of cellular lipid, can reduce the production of cellular fatty acid by inhibiting the activity of FAS, has a function of inhibiting the production and causing withering of microvascular endothelial cells, shows a broad-spectrum anti-tumor function in a cytotoxicity test of thirty-three tumor cell strains of a human body, and shows a function in strongly inhibiting the production of tumor, such as prostate cancer cells LnCAP, lung cancer cells NCI-H23 and colon cancer cells HCT-116 of a human body in a tumor transplantation nude mice model test. A pharmacokinetics test of the nor-icariin in the body of a little mouse proves that the nor-icariin can be kept with a certain concentration, good for better anti-humor effect. The acute toxicity test of the nor-icariin in the body of the mouse shows nontoxicity; therefore the nor-icariin is proved to be a newly-developed broad spectrum anti-humor drug with broad development prospect.
Owner:æ®·æ£ä¸° +1
Cyclo-pentapeptide with antineoplastic activity
InactiveCN101270154AGood antitumor activitySimple preparation processPeptidesCyclic peptide ingredientsPharmaceutical ResourcesWilms' tumor
The present invention discloses a cyclic pentapeptide with anti-tumour activity, which is cyclic (leucyl-N-methylleucyl-leucyl-leucyl-N-methylleucyl) and the constitutional formula of which is shown in the formula (I). The cyclic pentapeptide of the present invention is separated from galaxaura filamentosa in the South China Sea, and in vitro experiments show that the cyclic pentapeptide has strong inhibiting effect on human hepatoma cell lines (HepG2), human hepatoma cell lines (BEL-7402), human mammary cancer cell lines (MCF-7), human colon cancer cell lines (LOVO), human lung cancer cell lines (PC84045) and human nasopharyngeal cancer (CNE) and can keep the mitotic cycle of BEL-7402 hepatoma cells in G2 / M phase. The present invention provides a pilot compound for the research and the development of new anti-tumour drugs and is valuable for the exploitation of the marine pharmaceutical resources of China.
Owner:JINAN UNIVERSITY
Dehydroabietic acid benzimidazole derivatives with antitumor activity as well as preparation method and application of dehydroabietic acid benzimidazole derivatives
InactiveCN107501387ASteroidsAntineoplastic agentsBenzimidazole derivativeNitrogenous heterocyclic compound
The invention discloses dehydroabietic acid benzimidazole derivatives with antitumor activity as well as a preparation method and an application of the dehydroabietic acid benzimidazole derivatives. The dehydroabietic acid benzimidazole derivatives I-a to I-l with the structures shown in a general formula I and pharmaceutically acceptable salt of the derivatives are shown in the description, wherein corresponding Aryl of dehydroabietic acid benzimidazole derivatives I-a to I-l are shown in the description respectively. Nitrogen-containing heterocyclic compounds are pharmaceutically acceptable salt of the dehydroabietic acid benzimidazole derivatives and have good antitumor bioactivity. Pharmacology experiments prove that the compounds have a remarkable inhibition effect on hepatoma cell lines SMMC-7721, breast cancer cell lines MDA-MB-231 and colon cancer cell lines CT26.
Owner:NANJING FORESTRY UNIV
Method for producing epigallocatechin and gallic acid through transformation of aspergillus niger whole cell
ActiveCN104673845AImprove toleranceEfficient conversionMicroorganism based processesFermentationGallic acid esterDipotassium phosphate
The invention discloses a method for producing epigallocatechin and gallic acid through transformation of aspergillus niger whole cell. The whole cell biotransformation is performed by adopting the aspergillus niger; the whole cell biotransformation nutrient solution is a nutrient solution containing 1-20% of tea polyphenol or EGCG; the preservative number of the aspergillus niger RAF 106 strain is CGMCC NO.9608. The whole cell biotransformation nutrient solution comprises the following ingredients: 1-20% of tea polyphenol or EGCG, 0.03-0.8% of dipotassium phosphate, 0.1-3% of monopotassium phosphate, 0.03-0.7% of manganese sulfate, 0.3-2% of sodium chloride, 0.01-0.3% of magnesium sulfate and 0.02-2% of yeast or malt extract. By adopting the nutrient solution, the whole cell is transformed in one step, the transforming efficiency is high and the transformation can be finished within 20 hours, and the killing activity of the transformed product on the colon cancer cell is high.
Owner:SOUTH CHINA AGRI UNIV
Nucleic acid adapter used for detecting human high-metastasis colon cancer cell strain LoVo and detection kit
ActiveCN105385691AHigh affinityImprove featuresMaterial analysisDNA/RNA fragmentationNucleotideA-DNA
The invention discloses a nucleic acid adapter used for detecting a human high-metastasis colon cancer cell strain LoVo and a detection kit. The nucleic acid adapter is one of a nucleic acid adapter J1, a nucleic acid adapter J3, a nucleic acid adapter J4 and a nucleic acid adapter J7; the nucleotide sequence of the nucleic acid adapter J1 is a DNA fragment shown as SEQ ID NO.1; the nucleotide sequence of the nucleic acid adapter J3 is a DNA fragment shown as SEQ ID NO.2; the nucleotide sequence of the nucleic acid adapter J4 is a DNA fragment shown as SEQ ID NO.3; the nucleotide sequence of the nucleic acid adapter J7 is a DNA fragment shown as SEQ ID NO.4. The nucleic acid adapter is low in immunogenicity, small in molecular weight, easy to store and label and capable of serving as the detection kit to detect the human high-metastasis colon cancer cell strain LoVo.
Owner:HUNAN UNIV
Use of ursolic acid as colon tumor resistant medicament
InactiveCN101991579ABlock EGFR signaling pathwayOrganic active ingredientsAntineoplastic agentsSide effectApoptosis
The invention relates to use of ursolic acid as a colon tumor resistant medicament. The ursolic acid has the effects of inhibiting colon cancer / tumor cell proliferation and inducing apoptosis. In naked mouse in vivo experiments, the ursolic acid can effectively inhibit the proliferation of colon cancer transplanted tumor and inhibit the generation of tumor blood vessels, and has no obvious toxic or side effect on mice. The ursolic acid has the effect of inhibiting EGFR / MAPK signal channel phosphorylation of colon cancer cells, and the key target of the ursolic acid is to inhibit ERK1 / 2 protein phosphorylation. The ursolic acid which is synergetic with oxaliplatin serving as a clinical first-line chemotherapy medicament of the colon cancer has better curative effect. The ursolic acid has better proliferation inhibiting effect on the colon cancer cells of K-RAS gene mutation. The use of the ursolic acid as the colon tumor resistant medicament provides a new thought for treating the colon tumor.
Owner:ZHEJIANG UNIV
Novel beta-chloroethylnitrosourea compounds, and synthesis method and application thereof
ActiveCN104031048ADelay drug resistanceImprove targetingOrganic chemistryAntineoplastic agentsSynthesis methodsO6-Benzylguanine
The invention relates to novel beta-chloroethylnitrosourea compounds, and a synthesis method and application thereof. The structure of the beta-chloroethylnitrosourea compounds is disclosed as general formula (II). The in-vitro antitumor screening test on the compounds disclosed as general formula II proves that the compounds disclosed as general formula I have obvious inhibiting action on human cerebral nerve glioma cells SF763, SF767, SF126 and SF188, human colon cancer cell HT29, mouse leukaemia cell L1210 and many other tumor cell lines and have higher tumor inhibiting activity than the existing CENU and CENU / O6-benzylguanine combined medicine.
Owner:BEIJING UNIV OF TECH
Genes and polypeptides relating to hepatocellular or colorectal carcinoma
InactiveUS20060019252A1Compound screeningTumor rejection antigen precursorsWild typeColon cancer cell
The present application provides novel human genes WDRPUH and KRZFPUH and PPIL1 whose expression is markedly elevated in a great majority of HCCs and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in response to the transduction of wild-type APC1 into colon-cancer cells. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.
Owner:ONCOTHERAPY SCI INC
2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer
ActiveUS20100168417A1Prevent proliferationBiocideOrganic chemistryNon small lung cancerProstate cancer cell
2-indolyl imidazo[4,5-d]phenanthroline compounds of Formula I that are capable of intracellular chelation of transition metals and of exerting antiproliferative effects in cancer cells, that are cytostatic and / or cytotoxic, are provided. Compounds of Formula I can also induce apoptosis in cancer cells and are thus capable of exerting a cytotoxic effect on cancer cells. The compounds of Formula I are also capable of selectively inhibiting the proliferation of one or more of prostate cancer cells, colon cancer cells, non-small lung cancer cells and leukemia cells. The compounds of Formula I are also capable of increasing the expression of the zinc-regulated tumour suppressor, KLF4 and thus are useful in inhibiting the proliferation of cancer cells in which KLF4 functions as a tumour-suppressor, including, but not limited to, bladder cancer, cancers of the gastrointestinal tract and various leukemias.
![2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer](https://images-eureka.patsnap.com/patent_img/5b62d250-8752-49d5-a36e-f88e437ae6c6/US20100168417A1-20100701-D00000.png "2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer")
![2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer](https://images-eureka.patsnap.com/patent_img/5b62d250-8752-49d5-a36e-f88e437ae6c6/US20100168417A1-20100701-D00001.png "2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer")
![2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer](https://images-eureka.patsnap.com/patent_img/5b62d250-8752-49d5-a36e-f88e437ae6c6/US20100168417A1-20100701-D00002.png "2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer")
Owner:APTOSE BIOSCIENCES INC
Genes and polypeptides relating to hepatocellular or colorectal carcinoma
InactiveUS20080207549A1Compound screeningTumor rejection antigen precursorsWild typeColon cancer cell
The present application provides novel human genes WDRPUH and KRZFPUH and PPIL1 whose expression is markedly elevated in a great majority of HCC's and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in response to the transduction of wild-type APC1 into colon cancer cells. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target for developing drugs against the disease.
Owner:ONCOTHERAPY SCI INC +1
Pectin-5-efudix colon cancer double-target ahead body medicament and preparation method
InactiveCN101269087AGood treatment effectIncrease healing effect, improve selectivityOrganic active ingredientsPharmaceutical non-active ingredientsLymphatic SpreadColon cancer cell
The invention relates to a pectin-5-fluorouracil colon cancer two-targeting prodrug and the preparation method thereof, and mainly synthesizes a two-targeting prodrug for colon cancer by utilizing an anti-cancer drug, 5-fluorouracil (5-FU), and pectin. The two-targeting prodrug for colon cancer is used for treating colon cancer and is characterized in that the 6-digit carboxyl is utilized to be combined with 5-FU directly or through different bridging groups to synthesize a series of two-targeting prodrugs for colon cancer. The prodrug first targets 5-FU to the colon by utilizing pectin to realize colon positioned release, and then 5-FU-galactose is identified through high expression of colon cancer galactin-3, and then 5-Fu is targeted to the colon cancer cells to realize two-targeting of colon cancer to treat colon cancer. The prodrug improves the selectivity of 5-FU greatly, enhances the curative effect and reduces adverse reactions. In addition, the hydrolysis fragments of pectin play a role in resisting tumor metastasis and can have a synergic action with 5-FU. The pectin-5-fluorouracil two-targeting prodrug for colon cancer focuses on the drug design ideas of drug delivery, targeting and coordination; therefore, the prodrug achieves the goal of high selectivity, high efficiency and low toxicity.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, preparing method, composite and application thereof
The invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, a preparing method, an application and a drug composite containing the compound thereof. More specifically, the invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound as shown in the formula I, a preparing method and an application thereof. By the growth inhibition test of various tumour cell lines (human breast cancer cells MDA-MB-435, p53-deleted poorly differentiated colorectal adenocarcinoma cells Hct116p53- / -, p53-enriched poorly differentiated colorectal adenocarcinoma cells Hct116p53+ / +, human breast cancer cells Mcf-7, NIH189, human breast cancer cells SkBr-3, prostatic cancer cells LnCap, LnHer, human colorectal cancer cells HT29 and human ovarian cancer cellsHEY), the compound has favourable inhibition activity for the above tumour cells and can treat diseases caused by tumour cell malignant proliferation. The invention also discloses a drug composite containing the compound.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Method for extracting purple corn pigment
InactiveCN102229753AHigh purityEnergy saving productionChemical industryNatural dyesFiltration membraneCeramic composite
The invention relates to a method for extracting purple corn pigment. The purple corn pigment according with the conventional international standards is extracted by eleven steps, namely sorting and crushing, extraction with acid water, rough filtration and cooling, filtration of kieselguhr, filtration with a ceramic composite membrane, adsorption and desorption, concentration with a nano-filtration membrane, evaporation concentration, separation, spray drying, and obtaining of a finished product; the raw materials and the extraction equipment used in the extraction method are conventional materials and equipment, so the method is suitable for large-batch production; the extracted purple corn pigment has unique physiological functions of resisting oxidation, softening blood vessels, preventing and killing colon cancer cells and the like, and can be applied in the fields of food, health-care products and medicine; and the production mode is energy-saving and environment-friendly.
Owner:HUAIBEI PUHAO BIOLOGICAL TECH
Piperlongumine-ligustrazine heterocomplex, preparation method and medical application
The invention discloses a piperlongumine-ligustrazine heterocomplex, a preparation method and a medical application. The piperlongumine-ligustrazine heterocomplex is a compound, isomer or pharmaceutically acceptable salt as shown in the specific formula (I), wherein R1, R3 or R4 is independently selected from C1-3 alkyl groups or C1-3 alkoxygroups; R2 is selected from the hydrogen (H) or halogen. The compound has good water solubility, is higher in proliferation inhibition activity for 4 colon cancer cells than that of piperlongumine. The compound, the isomer or the pharmaceutically acceptable salt can be applied to respects of medicines for treating or preventing tumors, or applies to respects of medicines relevant to metastatic cancer, and can be applied to relevant diseases including but not limited to brain gliomas, colon cancer, metastatic colon cancer, cell lung cancer, myoblastosis and the like.
Owner:CHINA PHARM UNIV
1, 5-diaryl-1, 2, 4-triazole compounds and pharmacy use thereof
The invention discloses 1, 5-diaryl-1, 2, 4-triazole compounds or pharmaceutically acceptable salts thereof shown as structural formula (I)-(III), and pharmaceutical compositions containing the compounds. The invention also discloses application of the compounds or pharmaceutically acceptable salts thereof in preparation of drugs for treatment of various malignant tumors and tumor metastasis related diseases. The compounds shown as formula (I)-(III) can realize concentration gradient dependent inhibition of the proliferation, invasion, infiltration and the like of breast cancer cells, prostate cancer cells, colon cancer cells, liver cancer cells, non-small cell lung cancer cells, bladder cancer cells and other tumor cells, have low toxicity, and have wide application prospects in bio-pharmaceutical industry.
Owner:EAST CHINA NORMAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com